Logo

Interleukin Genetics Files to Raise up to $75M

Jan 07, 2010

NEW YORK (GenomeWeb News) – Interleukin Genetics has filed a shelf registration with the US Securities and Exchange Commission seeking to sell up to $75 million worth of stock or debt instruments.

The firm said in its SEC registration that it may offer shares of common stock and preferred stock, debt securities, warrants, or rights or contracts for any of those securities, either individually or in units.

The Waltham, Mass.-based genetic testing company is developing gene-based prediction tests for tooth loss, osteoporosis, heart health, bone health, and risk tests for other conditions.

As of Sep. 30, Interleukin held $1.4 million in cash and cash equivalents.

Interleukin Genetics' stock closed down 5 percent at $.77 per share in Wednesday trade on the American Stock Exchange.

Filed under

Diagnostics
genetic testing
Orig3n
Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.